Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.20.4
Consolidated Statements of Operations - USD ($)
12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Operating expenses:    
Research and development $ 9,877,555 $ 2,199,297
Acquired in-process research and development 6,826,495
General and administrative 7,533,722 2,509,041
Loss from operations (24,237,772) (4,708,338)
Interest income (expense) 20,677 (162,873)
Foreign exchange loss (48,020)
Net loss (24,265,115) (4,871,211)
Deemed dividend arising from warrant amendment (41,338,934)
Net loss attributable to common stockholders $ (65,604,049) $ (4,871,211)
Per share information:    
Net loss per share, basic and diluted $ (6.96) $ (0.91)
Weighted average shares outstanding, basic and diluted 9,420,484 5,348,195